Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SLS

+ Watchlist+ Portfolio

SELLAS Life Sciences Group, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$19.15
52-Week Range
$1.39 – $24.89
Market Cap
$3.66B
P/E (TTM)
—
EPS (TTM)
-0.20
Dividend Yield
0.00%
Advanced Metrics
Price/Book
27.70
PEG Ratio
—
Return on Equity
-40.31%
Return on Assets
-24.23%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
14.92
Debt/Equity
0.00
Total Debt
$599.00K
Free Cash Flow
$-14.92M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$3.53B

Market Snapshot

About

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies. The company focuses on therapies targeting acute myeloid leukemia and other blood cancers. Its lead product candidate is galinpepimut-S, a cancer immunotherapy designed to stimulate immune responses against malignant cells.